摘要
目的 建立测定二甲苯磺酸拉帕替尼片有关物质的高效液相色谱法。方法 采用Waters Xterra MS C18色谱柱(4.6 mm×250 mm,5 μm);以0.01 mol·L-1磷酸二氢钠溶液(用磷酸调节pH值至3.2)为流动相A,以乙腈为流动相B,梯度洗脱,流速1.0 mL·min-1;检测波长265 nm,柱温40 ℃。结果 拉帕替尼杂质A、拉帕替尼杂质2和拉帕替尼杂质1分别在0.02~8.08、0.02~8.26和0.02~8.29 mg·mL-1内线性关系良好, r≥0.999 9,定量限分别为1.0、1.4、2.1 ng,杂质高、中、低浓度的平均回收率(n=9)在100.2%~102.9%,RSD(n=9)在0.02%~0.66%,可以满足杂质分析的要求。结论 本方法简便、准确、专属性强,可定量测定二甲苯磺酸拉帕替尼片的有关物质。
Abstract
OBJECTIVE To establish a determination method of the related substances of lapatinib ditosylate tablets by HPLC. METHODS Waters Xterra MS C18 column (4.6 mm×250 mm, 5 μm) was selected; 0.01 mol·L-1 sodium dihydrogen phosphate solution (pH adjusted to 3.2 with phosphoric acid) was mobile phase A, acetonitrile was mobile phase B, and gradient elution was used at a flow rate of 1.0 mL·min-1. The detection wavelength was set at 265 nm, and the column temperature was 40 ℃. RESULTS Lapatinib Impurity A, LAPA-2 and LAPA-1 had good linearity in the range of 0.02-8.08, 0.02-8.26 and 0.02-8.29 mg·mL-1, respectively (r ≥ 0.999 9). The limits of quantitation (LOQ) were 1.0, 1.4, and 2.1 ng, respectively. The average recovery (n=9) was in the range of 100.2%-102.9%, and RSDs (n=9) were in the range of 0.02%-0.66%. CONCLUSION The method is simple, accurate, and specific and can quantitatively determine the related substances of lapatinib ditosylate tablets.
关键词
高效液相色谱法 /
二甲苯磺酸拉帕替尼片 /
拉帕替尼杂质A
{{custom_keyword}} /
Key words
HPLC /
lapatinib ditosylate tablet /
related substance /
lapatinib impurity A
{{custom_keyword}} /
刘俊华,梁星晖,王斌荣.
高效液相色谱法测定二甲苯磺酸拉帕替尼片有关物质[J]. 中国药学杂志, 2013, 48(8): 644-648 https://doi.org/10.11669/cpj.2013.08.018
LIU Jun-hua, LIANG Xing-hui,WANG Bin-rong.
Determination of Related Substances in Lapatinib Ditosylate Tablets by HPLC[J]. Chinese Pharmaceutical Journal, 2013, 48(8): 644-648 https://doi.org/10.11669/cpj.2013.08.018
中图分类号:
R917
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
ZHAN Q. Lapatinib in breast cancer treatment . J Int Oncol(国际肿瘤学杂志),2007,34(8):596-599.
SFDA CDE.Technical guidelines for chemical drug impurities(化学药物杂质研究的技术指导原则).SFDA CDE,2007.http://www.cde.org.cn/attachmentout.do?mothed=list&id=161.
GlaxoSmithKline. . FDA,2010.http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s3s6lbl.pdf.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}